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Background: Despite the benefits of beta-blockers in patients with established or sub-clinical coronary artery
disease, their use in patients with chronic obstructive pulmonary disease (COPD) has been controversial. Currently,
no systematic review has examined the impact of beta-blockers on mortality in COPD.
Methods: We systematically searched electronic bibliographic databases including MEDLINE, EMBASE and Cochrane
Library for clinical studies that examine the association between beta-blocker use and all cause mortality in patients
with COPD. Risk ratios across studies were pooled using random effects models to estimate a pooled relative risk
across studies. Publication bias was assessed using a funnel plot.
Results: Our search identified nine retrospective cohort studies that met the study inclusion criteria. The pooled
relative risk of COPD related mortality secondary to beta-blocker use was 0.69 (95% CI: 0.62-0.78; I2=82%).
Conclusion: The results of this review are consistent with a protective effect of beta-blockers with respect to all
cause mortality. Due to the observational nature of the included studies, the possibility of confounding that may
have affected these results cannot be excluded. The hypothesis that beta blocker therapy might be of benefit in
COPD needs to be evaluated in randomised controlled trials.
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Beta-blockers are one of the most prescribed classes of
cardiovascular medications. In clinical trials they have
been shown to lower morbidity and mortality secondary
to congestive heart failure [1] (CHF) and coronary artery
disease (CAD) [2]. Chronic Obstructive Pulmonary Dis-
ease (COPD) is a progressive debilitating lung disease
and currently the third leading cause of death in North
America [3]. Many patients with COPD also have con-
comitant CAD. There has been uncertainty with regard
to using beta-blockers in COPD patients mainly because
of concerns that they might induce bronchospasm and
worsen lung function [4], especially in those patients
who have a combination of asthma and COPD.* Correspondence: metminan@popi.ubc.ca
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reproduction in any medium, provided the orDespite these concerns, there is emerging evidence
that beta-blockers may be beneficial in patients with
COPD [5,6]. In one systematic review of 19 randomised
controlled trials that included patients with both asthma
and COPD, beta-blockers lowered FEV1 by 7.46% (95%
CI, 5.59%-9.32%) [4]. Results from this meta-analysis
prompted guidelines to recommend the use of low dose
beta-blockers in COPD patients [7].
Recent studies have also shown that beta-blockers may
lower mortality in COPD patients [8,9]. This potential
benefit may arise from a possible protective effect of beta-
blockers in patients with established CAD in whom these
drugs may be underused. Beta-blockers may also be bene-
ficial in patients with CAD and overlapping CHF. Finally,
similar to statins, beta-blockers, especially cardio-selective
beta-blockers such as carvedilol, may exert pleiotropic
effects including antioxidant and alpha-adrenorecptor
blocking properties [10]. As of to date, no systematic re-
view specifically addressing mortality benefit with beta-
blockers in COPD patients has been conducted. We
sought to address these questions with respect to al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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undertaking a systematic review and meta-analysis.Methods
Search strategy
We searched the following databases to identify pertin-
ent studies that examined the association between beta-
blockers and all cause mortality: MEDLINE (1966 to
March 2012), EMBASE (1980 to March 2012), Cochrane
Central Register of Controlled Trials (1991 to March
2012), Database of Abstracts of Reviews of Effects (1991
to March 2012), ACP Journal Club (1991 to March
2012), International Pharmaceutical Index (1970 to
March 2012), BIOSIS Previews (1969 to March 2012)
and Web of Science (1961 to March 2012). The initial
search strategy was developed from the following MeSH
subject headings COPD, Acebutolol, Atenolol, Betaxolol,
Bisoprolol, Celiprolol, Esmolol, Metoprolol, Alprenolol,
Bucindolol, Carteolol, Carvedilol, Labetalol, Nadolol,
Penbutolol, Pindolol, Propranolol, Sotalol, Timolol, adre-
nergics, and Beta-blockers in MEDLINE. We reviewed
titles for relevance from this search and examined all
subject headings and abstracts. The scope notes in
MEDLINE and EMBASE were also examined to ensure
the correct subject headings were used based on their
definitions; other subject headings were included based
on previous indexing and the inclusion of keywords
based on synonyms used in the scope notes. Proceedings
and conference abstracts were searched through the
databases PapersFirst (1993) and ProceedingsFirst (1993)
up to March 2012. Authors’ names and year of pub-
lished work from key papers were entered into the cited
reference search in the Web of Science. We screened
the references of retrieved studies and review articles for
any potentially missed articles. In addition, we hand
searched the reference lists of retrieved studies as well as
journals related to “pharmacology”, “respirology”, pul-
monary”, abstracts and books related to respiratory or
lung diseases. There was no language restriction in
selecting the studies.Selection criteria
We considered all experimental or observational studies
that assessed the association between beta-blocker use
and mortality in COPD patients. Studies were included
if they 1) clearly defined COPD as either primary or sec-
ondary outcomes; 2) clearly defined beta-blocker use as
either a primary exposure in the study or used in a sub-
group of patients with COPD; 3) presented relative risks
or odds ratios (for all cause mortality) and their corre-
sponding confidence intervals or provided enough data
to compute these parameters.Data extraction
Included articles were reviewed in full by two reviewers
independently (ME and SJ). Study characteristics
included in the data extraction form were as follows:
authors’ names, publication year, country of study, study
design, sample size, study population type, mean or age
range, gender of participants, type of risk factors or con-
founders adjusted for, outcome of the interest (mortality
reduction), adjusted odds ratio or relative risks (RRs),
and 95% confidence intervals (CIs).
Statistical analysis
The primary analysis examined the association between
beta-blocker (both selective and non-selective) use and
mortality in COPD patients. We weighted the study-
specific adjusted relative risks (RRs) for cohort studies
by the inverse of their variances. Due to the observa-
tional nature of the studies, we used the random effects
model to estimate the pooled adjusted RR. Statistical
heterogeneity between studies was evaluated with
Cochran's Q test and the I2 statistic. Sensitivity analysis
was assessed using the Jackknife procedure by looking at
the individual influence of a study and then repeating
the analysis by excluding the studies with the largest
weights.
Results
Our search resulted in nine retrospective cohort studies
[5,6,8,9,11-15] that met our inclusion criteria (Figure 1).
Five studies looked at subjects with COPD [11-15] who
also had vascular disease or chronic heart failure
(Table 1). Three studies looked at concurrent beta-
blocker and beta agonist use [8,9,13]. The pooled relative
risk of COPD related mortality secondary to beta-
blocker use was 0.69 (95% CI: 0.62-0.78; I2=82%, p-
value=0.00001). Our results indicate a high degree of
heterogeneity among the included studies (Figure 2). In
a sensitivity analysis, we identified one study [11] as the
source of heterogeneity. Exclusion of this study from the
analysis removed the study heterogeneity (I2=29%,
P=0.20) while the pooled RR stayed significantly protect-
ive (RR=0.74, 95% CI=0.70-0.79). Examination of the fun-
nel plot revealed presence of publication bias. The funnel
plot clearly demonstrates that studies with a null or posi-
tive association which should appear symmetrically on
the right axis to form the funnel are missing (Figure 3).
This means that studies that did not find a protective as-
sociation for beta-blockers and mortality in COPD
patients (negative studies) were less likely to be
published.
Discussion
The results of this systematic review are consistent with
a mortality benefit with beta-blockers in subjects with
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Figure 1 Selection of studies for inclusion in the systematic
review and meta-analysis.
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amongst the studies. The source of heterogeneity was
found to be from the study by Gottlieb et al [11]. The
study by Gottlieb et al [11] was a retrospective analysis
of those taking beta-blockers who had a previous history
of myocardial infarction. The authors only reported a
rate ratio of mortality amongst users of beta-blockers
with a diagnosis of COPD. It is unclear from this study
whether this reported rate ratio was adjusted for poten-
tial confounders.
Beta-blockers are a popular class of cardiovascular
drugs used for multiple cardiovascular conditions in-
cluding hypertension, congestive heart failure and
management of ischemic heart disease. The possibilityof bronchospasm with beta-blocker therapy in COPD
may have discouraged some clinicians from prescribing
these drugs to their COPD patients especially those
with concomitant cardiovascular disease. In recent
years, there has been emerging literature pointing to-
ward a protective effect from beta-blockers in COPD
[5,6,8]. A systematic review by Salpeter and colleagues
assessed the effect of beta-blockers in randomised
trials of patients with asthma or COPD [4]. The review
found that beta-blockers decreased FEV1 by 7.46%
(95% CI, 5.59%-9.32%) and increased response to beta
agonists by 4.63% (95% CI, 2.47%-6.78%) [4]. The limi-
tation of this review was that it included patients with
both asthma and COPD. A recent review completed
by the same investigators failed to show any benefit or
harm with cardioselective beta-blockers on FEV1 in
COPD patients [16].
The mortality benefits of beta-blockers in COPD are
thought to be due to the cardioprotective effect of the
drugs. Two other postulated mechanisms may also ex-
plain the potential benefits of beta-blockers in COPD.
Increased beta-agonist activity has shown to play an im-
portant role in the pathology of CHF [17,18]. Thus
patients taking beta-blockers with concomitant COPD
and CHF may experience a lower degree of beta agonist
stimulation.
Finally, it is yet unclear as to whether a protective
effect with these drugs is a class-effect or whether this
benefit differs with the receptor selectivity (B1 selective
vs non-selective such as carvedilol). Carvedilol has
shown to have pleiotropic properties including antioxi-
dant exerting effects [10] and has shown to lower
mortality in patients with CHF. Thus, carvediolol’s
mortality reduction in COPD patients may be more
profound than that of beta-selective beta-blockers. It is
possible that the beneficial effects of beta-blockers go
beyond their cardioprotective properties. Heindl et al.
examined the sympathetic nerve activity in six COPD
patients with no previous history of coronary artery
disease and six healthy controls [19]. COPD subjects
showed a significantly higher peripheral sympathetic
activity than the controls. Rutten et al. assessed the ef-
fect of beta-blockers in a sub-group of COPD patients
with less severe coronary artery disease [9]. The rela-
tive risk of mortality amongst COPD patients who
used beta-blockers and only had hypertension was
similar to those with more severe form of coronary ar-
tery disease (RR=0.67, 95% CI: 0.45-0.99: RR=0.68, 95%
CI: 0.56-0.83 respectively).
This review, as with all systematic reviews of observa-
tional studies, has limitations. None of the studies were
randomised trials and although statistical adjustment
was used in all the studies to control for potential con-
founders, not all confounding variables could have been
Table 1 Characteristics of included studies in the systematic review
Study Design Sample size and
cohort description
Type of BB Relative Risk* Covariates




Cardio-selective 0.78 (0.67-0.92) CAD and Respiratory disease,
age, sex, diabetes, smoking,
FEV1, cardiovascular drugs













Not specified 0.39 (0.14-0.99) Age, CHD, CHF, Liver disease,
COPD exacerbations,
malignancy, smoking, FEV
























Not specified 0.60 (0.57-0.63) Not specified





Not specified 0.55 (0.37-0.82) Not specified





Cardio-selective 0.73 (0.60-0.88) Age, sex, hypertension,
hypercholesterolemia,
diabetes, renal function,
smoking, BMI, CAD, FEV1,
cardiovascular drugs





and COPD or Asthma
Not specified 0.86 (0.73-1.0) Age, gender, co-morbidities,
CAD, cardiovascular drugs,
physician speciality
Hawkins (2009) [15] Retrospective
Cohort
1,258 patients with COPD
and previous history of MI
Not specified 0.74 (0.68-0.80) Not specified
* = Relative risk and 95% confidence interval for beta-blocker use and mortality in COPD.
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blocker use was also incomplete in most of the studies
and did not provide information on the patterns of ex-
posure including, adherence or a dose–response relation
for beta-blockers in their relation to COPD mortality.
Moreover, many of the studies did not describe in detail
how mortality data was obtained. Finally, several types of
biases specific to pharmacoepidemiologic studies of re-
spiratory disease may have potentially affected the
results of the studies included in this review. We briefly
discuss four types of biases including immortal time
bias, immeasurable time bias, calendar time bias and
confounding by contraindication.Selection bias
Selection bias refers to systematic differences between
the exposed and unexposed groups in a cohort study.
One example of study that may have been affected by se-
lection bias is the study by Au et al [6]. In this study,antihypertensive use was defined as adherence to a
medication of 80% or more during the 90 days prior to
the event date [6]. Beta-blockers are generally less toler-
ated than calcium channel blockers mainly due to a less
favourable adverse events profile. Thus beta-blocker
users may have been ‘healthier’ than calcium channel
blocker users and hence may have had a lower overall
mortality.Immortal time bias
Immortal time bias, first described by Suissa [20], refers
to a type of bias that arises mainly from pharmacoepide-
miologic studies that use health claims databases. The
bias occurs when there is a period of time where drug
exposure information prior to hospitalization is missing,
as health claim databases usually do not capture in-
hospital prescription drug data. Since cases are more
likely to experience multiple hospitalizations possibly
leading to death, they are less likely to be prescribed a
Figure 2 Forest plot of association between beta-blockers and COPD mortality.
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patients [20]. Thus, a lower probability of exposure
amongst the cases may lead to a biased protective rate
ratio. In this review, the study by Dransfield et al [5] had
access to in-hospital medication which makes the possi-
bility of this bias unlikely. However, in the studies that
used health claim databases [6,11] the possibility that
immortal time bias may have influenced the study
results was not discussed and thus cannot be excluded.
Calendar time bias
Calendar time bias refers to a bias that may be caused
by time-trends that may lead to differential prescribing
of one drug over another. For example, the Study by Au
et al [6] compared the risk of mortality amongst COPD
patients who took beta-blockers to those who took other
antihypertensives including calcium channel blockers.
Antihypertensive drug therapies especially calcium chan-
nel blockers’ prescribing trends may vary in time and
may be affected by publication of land-mark trials,
hypertension guidelines or changes in policy. Thus
changes in antihypertensive prescribing over time may
lead to differential prescribing of antihypertensives
which may also affect COPD patients.Figure 3 Funnel plot of studies of beta-blocker use and
mortality in patients COPD.Confounding by contraindication
Confounding by indication is possibly the most import-
ant type of confounding that threatens the validity of
pharmacoepidemiologic studies. This type of confound-
ing refers to a situation where the observed association
with a drug is in fact due to the condition for which the
drug is used. Confounding by contraindication is inher-
ently the opposite of this situation where the drug is
knowingly withheld by a clinician due to concerns that
the drug may worsen a patient’s condition. Beta-blocker
use in COPD is a classic example where confounding by
contra-indication may occur as historically clinicians
have been hesitant in prescribing beta-blockers to COPD
patients. This type of confounding may explain the pro-
tective effect observed with beta-blockers in the COPD
population mainly due to a small number of patients
with COPD who received beta-blockers compared to
other types of antihypertensives. Another possibility is
that clinicians may prescribe beta-blockers to those with
a less severe form of COPD who may have a lower risk
of mortality.Conclusion
The mortality benefit from this review is similar in mag-
nitude to that of statins which have been previously
studied in this setting [21,22] and are currently being
tested in randomised controlled trials [23]. Although the
results of this review are consistent with a protective ef-
fect of beta-blockers and COPD mortality, several types
of biases may have affected these results. We believe that
our review generates a strong hypothesis that beta-
blockers may have mortality benefit in COPD patients.
However, this potential benefit must be critically exam-
ined in a large RCT. Patients with underlying COPD
who are already receiving beta-blockers for other med-
ical conditions may benefit from beta-blocker therapy.
However, initiation of beta-blocker therapy in COPD
patients to achieve mortality benefit must be reserved
until results from RCTs specifically addressing this ques-
tion are available.
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